天大藥業有限公司
TIANDA PHARMACEUTICALS LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00455)

VOLUNTARY ANNOUNCEMENT
DRUG REGISTRATION APPROVAL OF "IBUPROFEN SUSPENSION"

This announcement is made by Tianda Pharmaceuticals Limited (the "**Company**") on a voluntary basis. The purpose of this announcement is to keep the shareholders of the Company and potential investors informed of the latest business development of the Company. Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd., a wholly-owned subsidiary of the Company, has been granted the drug registration approval of Ibuprofen suspension (the "**Product**") by the National Medical Products Administration of the People's Republic of China.

The main ingredient of the Product is ibuprofen, and is mainly used for fever caused by common cold or influenza and for relieving of mild to moderate pain in Children such as headache, joint pain, migraine, toothache, muscle pain and neuralgia.

The Product is registered under type 4 chemical drug and is regarded as passing the consistency evaluation upon receiving the drug registration approval. The Product will further enrich and improve the Company's product portfolio and strengthen the Company's advantages in pediatric fields. The Company is prepared for the possible future centralized procurement of ibuprofen suspension and further expand its market share in hospitals. After years of R&D investment, the Group's R&D has entered the harvest period. Including the new ibuprofen product, a total of 7 new varieties are expected to be launched in 2024 and 2025, laying a solid foundation for future steady development.

By order of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 11 June 2024

As at the date of this announcement, the executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive Directors are Mr. ZHONG Tao and Mr. FENG Quanming; and the independent non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Dr. XIAN Yanfang.